MDMA Assisted Therapy for Bulimia Nervosa: A Treatment Development Protocol
This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can serve as a new treatment for BN. Participants are assigned to one of three groups: MDMA-AT, MDMA-AT-BN, and Standard Treatment (ST). MDMA groups include three experimental session that include dosing, which are each followed by three integrative sessions and also include 12 psychotherapy sessions. A follow-up will take place at 6-months post baseline.
- Status
- recruiting
- Phase
- Phase 1
- Institution
- Icahn School of Medicine at Mount Sinai
- Principal investigator
- Tom Hildebrandt, PsyD
- Start date
- 2026-05-22
- End date
- 2028-04-30
- Registry ID
- NCT07542145
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.